StartDEVA • IST
add
Deva Holding AS
Seneste lukkekurs
64,35 ₺
Dagsinterval
64,50 ₺ - 66,65 ₺
Årsinterval
51,00 ₺ - 81,75 ₺
Markedsværdi
13,28 mia. TRY
Gns. volumen
969,51 t
P/E-værdi
40,10
Udbytteprocent
-
Primær børs
IST
Markedsnyheder
Invezz
for 10 timer siden
Dow Jones-futures falder, da olie stiger på grund af Mellemøstens spændinger
1,61 %
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (TRY) | sep. 2025info | År til år-ændring |
|---|---|---|
Indtægt | 4,47 mia. | -8,27 % |
Driftsudgifter | 1,55 mia. | 29,60 % |
Nettoindtægt | -20,81 mio. | 94,15 % |
Overskudsgrad | -0,47 | 93,55 % |
Earnings per share | — | — |
EBITDA | 237,92 mio. | -77,02 % |
Effektiv afgiftssats | 84,84 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (TRY) | sep. 2025info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 2,49 mia. | -12,84 % |
Samlede aktiver | 35,50 mia. | 22,79 % |
Samlede passiver | 9,02 mia. | -1,21 % |
Samlet egenkapital | 26,48 mia. | — |
Shares outstanding | 200,02 mio. | — |
Kurs/indre værdi | 0,49 | — |
Afkast af aktiver | -0,75 % | — |
Afkast af kapital | -0,83 % | — |
Pengestrøm
Nettoændring i likviditet
| (TRY) | sep. 2025info | År til år-ændring |
|---|---|---|
Nettoindtægt | -20,81 mio. | 94,15 % |
Pengestrøm fra drift | 1,53 mia. | -32,16 % |
Pengestrøm fra investering | -517,27 mio. | 61,38 % |
Pengestrøm fra finansiering | -750,38 mio. | -25,01 % |
Nettoændring i likviditet | 243,03 mio. | 53,78 % |
Fri pengestrøm | -620,67 mio. | 22,50 % |
Om
DEVA Holding A.Ş. is a leading Turkish pharmaceutical company founded in 1958. As of 2024, it ranked 3rd in unit sales and 6th in TL sales in Turkey’s pharmaceutical market.
The company operates three EU GMP- and US FDA-approved facilities in Çerkezköy and Kartepe, with an annual production capacity of 620 million units. DEVA’s portfolio covers 10 therapeutic areas, including cardiovascular, dermatology, ophthalmology, hematology, and anti-infectives, and includes 1,404 registered products across 82 countries.
Recognized as Turkey’s top pharmaceutical company in R&D spending by Turkishtime’s 2024 R&D 250 Report, DEVA employs over 500 researchers and 3,000 staff in total. Guided by sustainability and innovation, the company focuses on developing accessible, effective, and environmentally responsible healthcare solutions for both domestic and global markets. Wikipedia
Grundlagt
22. sep. 1958
Website
Ansatte
3.036
